An Update on the Long-Term Safety Experience of Ixekizumab: Results from the Psoriasis Clinical Development Program with More than 3 Years of Follow-up from 12 Clinical Trials and More Than 15000 Patient-Years of Exposure to Ixekizumab

Main Article Content

April Armstrong
Noah Agada
Wen Xu
Gaia Gallo



Abstract not available.


Disclosures: Study sponsored by Eli Lilly & Company.


Copyright 2018 SKIN

Most read articles by the same author(s)

1 2 > >>